Acadia Pharmaceuticals Inc. (ACAD) is a publicly traded Healthcare sector company. As of May 21, 2026, ACAD trades at $20.94 with a market cap of $3.54B and a P/E ratio of 9.34. ACAD moved +2.25% today. Year to date, ACAD is -19.89%; over the trailing twelve months it is -3.41%. Its 52-week range spans $13.40 to $28.35. Analyst consensus is strong buy with an average price target of $32.77. Rallies surfaces ACAD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What do analysts rate ACAD?
15 analysts cover ACAD: 0 strong buy, 12 buy, 3 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $32.77.
Kihara James sold 1.33K (~$29.02K) on May 4, 2026.
Schneyer Mark C. sold 3.51K (~$76.40K) on May 4, 2026.
Schneyer Mark C. sold 2.71K (~$60.14K) on Apr 7, 2026.
Common questions about ACAD
What do analysts rate ACAD?
15 analysts cover ACAD: 0 strong buy, 12 buy, 3 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $32.77.
Does Rallies show ACAD price targets?
Yes. Rallies tracks ACAD analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is ACAD research on Rallies investment advice?
No. Rallies provides research, data, and educational context for ACAD. It does not provide personalized investment advice.
